Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Nachman

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
The Journal of Pediatrics|May 25, 2012
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virusJorge Lujan-Zilbermann, Meredith G Warshaw, Paige L Williams, et al.
Human Vaccines & Immunotherapeutics|February 2, 2013
High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)Adriana Weinberg, Petronella Muresan, Terence Fenton, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
Pediatrics|July 3, 2003
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infectionSharon Nachman, Soyeon Kim, James King, et al.
Child Psychiatry and Human Development|January 23, 2024
Are Family Factors Differentially Associated with Externalizing Symptoms Among Youth with Perinatally Acquired HIV?Deborah A G Drabick, Rafaella J Jakubovic, Abbey L Friedman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescentsGeorge K Siberry, Paige L Williams, Jorge Lujan-Zilbermann, et al.
Journal of the Pediatric Infectious Diseases Society|December 24, 2013
Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and YouthRobert F Pass, Sharon Nachman, Patricia M Flynn, et al.
The Lancet. Global Health|March 28, 2025
Strengthening the paediatric clinical trial ecosystem to better inform policy and programmesJames A Berkley, Judd L Walson, Glenda Gray, et al.
The Journal of Infectious Diseases|May 23, 2012
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adultsPatricia M Flynn, Sharon Nachman, Petronella Muresan, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
The Journal of Pediatrics|May 25, 2012
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virusJorge Lujan-Zilbermann, Meredith G Warshaw, Paige L Williams, et al.
Human Vaccines & Immunotherapeutics|February 2, 2013
High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)Adriana Weinberg, Petronella Muresan, Terence Fenton, et al.
The Pediatric Infectious Disease Journal|October 12, 2011
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected childrenGeorge K Siberry, Meredith G Warshaw, Paige L Williams, et al.
Pediatrics|July 3, 2003
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infectionSharon Nachman, Soyeon Kim, James King, et al.
Child Psychiatry and Human Development|January 23, 2024
Are Family Factors Differentially Associated with Externalizing Symptoms Among Youth with Perinatally Acquired HIV?Deborah A G Drabick, Rafaella J Jakubovic, Abbey L Friedman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescentsGeorge K Siberry, Paige L Williams, Jorge Lujan-Zilbermann, et al.
Journal of the Pediatric Infectious Diseases Society|December 24, 2013
Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and YouthRobert F Pass, Sharon Nachman, Patricia M Flynn, et al.
The Lancet. Global Health|March 28, 2025
Strengthening the paediatric clinical trial ecosystem to better inform policy and programmesJames A Berkley, Judd L Walson, Glenda Gray, et al.
The Journal of Infectious Diseases|May 23, 2012
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adultsPatricia M Flynn, Sharon Nachman, Petronella Muresan, et al.
Pageof 11